Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry

JAAD Int. 2024 Feb 12:15:127-130. doi: 10.1016/j.jdin.2023.11.015. eCollection 2024 Jun.

Jonathan I Silverberg¹, Angel Cronin², Eric A Jones², Swapna S Dave², Robert R McLean², Jeffrey Greenberg², Bruce Strober^{3

4}, Thomas Bieber^{5

6}, Melinda Gooderham^{7

8}, Amy S Paller⁹, Eric L Simpson¹⁰

¹ Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia.
² CorEvitas, LLC, Waltham, Massachusetts.
³ Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
⁴ Central Connecticut Dermatology, Cromwell, Connecticut.
⁵ Department of Dermatology and Allergology, University Hospital of Bonn, Bonn, Germany.
⁶ Christine Kühne - Center for Allergy Research and Education, Davos, Switzerland.
⁷ SKiN Centre for Dermatology and Probity Medical Research, Peterborough, Canada.
⁸ Queen's University, Kingston, Canada.
⁹ Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
¹⁰ Department of Dermatology, Oregon Health & Science University, Portland, Oregon.

No abstract available

Keywords: QoL; atopic dermatitis; biologic therapy; biologics; outcomes; quality of life; small molecule therapy; treatment response.